Highlighting the Benefits of Therapeutic Gardens in Alzheimer's Disease by 18F-FDG Cerebral PET /CT (JAZTEP)

The Alzheimer's Plan 2008-2012 allowed the installation of therapeutic gardens for the structures welcoming patients with Alzheimer's disease (AD) . The physical, psychological and social benefits are the improvement of the state of health and overall well-being.

There is a positive role in social interactions for patients with AD who can walk in the therapeutic gardens. Indeed, this promotes meetings with caregives and other people.

Using the garden decreases the stress level in patients (Ulrich). The therapeutic garden named "art, memory and life" in NANCY is based on art, nature and regional culture.

This garden can break with the "artificial" framework of care services often perceived as stressful.

In the garden, people walk around and have an experience that could improve self-image perception.

A clinical study with 2 groups of AD patients hospitalized in UCC or Cognitive Behavioral Unit took place in Nancy. The evaluation of the QCS (questionnaire on self-awareness) was carried out at the beginning and at the end of the study,

• a group of patients went into the garden: the QCS score increased
• a group of patients did not go to the garden (they remained in UCC): the QCS score decreased

Study Overview

• Status: Withdrawn
• Conditions: Alzheimer Disease
• Intervention / Treatment: Device: cerebral 18F-FDG PET-CT

• Study Type: Interventional
• Phase: Not Applicable

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patient with AD in the mild to moderate stage, followed at the memory and resource center (CMRR) (MMS 15-23) and having had a 18F-FDG PET-CT (Positon emission tomography) scan in routine care having a companion for the duration of the study .
• Patient with a neuropsychological assessment (MOCA, DO80, BREF, HAD) of less than 3 months. (If the last neuropsychological assessment dates from more than 3 months, these tests are carried out in routine care during the consultation was proposed and the consent obtained)
• Symptomatic treatment of AD (anticholinesterase or memantine) if prescribed, at a stable dose for 1 month, stable psychotropic treatment for 1 month
• Person affiliated with a social security scheme or beneficiary of such a scheme.
• Patient over 18 years old.
• Person received complete information on the organization of the research and having signed their informed consent.

Exclusion Criteria:

• Patient who did not have biomarkers identified by lumbar puncture
• Patient unable to perform a cerebral 18F-FDG PET-CT scan (lying position for more than 20 minutes)
• Patient unable to follow the therapeutic program of the garden.
• Woman of childbearing age whitout effective contraception.
• Pregnant woman or nursing mother.
• Person referred to in articles L. 1121-5, L. 1121-7 and L1121-8 of the public health code.
• Persons deprived of their liberty by a judicial or administrative decision, persons subject to psychiatric treatment under articles L. 3212-1 and L. 3213-1

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: one group; patients with mild or moderate Alzheimer disease	Device: cerebral 18F-FDG PET-CT; cerebral 18F-FDG PET-CT exam after walking in the garden while 2 weeks (75 minutes/per day from Monday to Friday)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
cerebral 18F-FDG PET-CT exam	Topography of brain regions, whose carbohydrate metabolism has significantly changed in cerebral PET / CT with 18F-FDG before and after using the Therapeutic Garden.	up 20 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
cerebral 18F-FDG PET-CT exam	Topography of the brain regions, the carbohydrate metabolism of which has been significantly modified in cerebral PET / CT with 18F-FDG before and after the use of the therapeutic garden by people living with Alzheimer's disease by integrating the actimetry as co-variable in the model.	up 20 days
Comparison of QCS before and after using the therapeutic garden	QCS is a self-awareness survey to be asked to patients before and after using garden	up 18 days
cerebral 18F-FDG PET-CT exam with QCS	Topography of brain regions, whose carbohydrate metabolism covariates with clinical variables (QCS).	up 20 days
Modifications of the score of the electrodermal response during the use of the garden	Electrodermal response is measured with sensors placed on the skin	up 14 days
cerebral 18F-FDG PET-CT exam with neuropsychological assessment	Topography of brain regions, whose carbohydrate metabolism covariates with clinical neuropsychological assessment	up 20 days

Collaborators and Investigators

• Sponsor: Central Hospital, Nancy, France

Study record dates

Study Major Dates

• Study Start (Anticipated): August 2, 2022
• Primary Completion (Anticipated): October 6, 2022
• Study Completion (Anticipated): January 2, 2023

Study Registration Dates

• First Submitted: August 10, 2020
• First Submitted That Met QC Criteria: August 12, 2020
• First Posted (Actual): August 14, 2020

Study Record Updates

• Last Update Posted (Actual): August 24, 2022
• Last Update Submitted That Met QC Criteria: August 23, 2022
• Last Verified: August 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Neurodegenerative Diseases; Dementia; Tauopathies; Alzheimer Disease; Molecular Mechanisms of Pharmacological Action; Radiopharmaceuticals; Fluorodeoxyglucose F18
• Other Study ID Numbers: A202012345

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No